Fluoxetine: An update of its use in major depressive disorder in adults;Épisode dépressif majeur: Dix ans d'expérience thérapeutique avec la fluoxétine

Encephale

Volumn 30, Issue 4, 2004, Pages 392-399

  Gourion, D ^a   Perrin, E ^b,d   Quintin, Ph ^c  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b Laboratoires Lilly   (France)

^c HÔPITAL LOUIS MOURIER   (France)

^d NONE

Author keywords

Clinical trials; Fluoxetine; Major depressive disorder; Properties

Indexed keywords

ADRENERGIC RECEPTOR; AMITRIPTYLINE; AUTORECEPTOR; CHOLINERGIC RECEPTOR; FLUOXETINE; HISTAMINE RECEPTOR; MONOAMINE OXIDASE INHIBITOR; NORFLUOXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL TRIAL; FIRST PASS EFFECT; HOMEOSTASIS; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; NERVE CELL PLASTICITY; NEUROTRANSMISSION; PHARMACODYNAMICS; RECEPTOR DOWN REGULATION; REVIEW; SIDE EFFECT; ADULT; ANXIETY; FEMALE; MALE; STATISTICS; SUICIDE ATTEMPT;

ADULT; ANXIETY; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; HUMANS; MALE; SEROTONIN UPTAKE INHIBITORS; SUICIDE, ATTEMPTED;

EID: 5744225756     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0013-7006(04)95453-x     Document Type: Review

References (57)

1. AGUGLIA E, CASACCHIA M, CASSANO GB et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993; 8(3): 197-202.
2. AHCPR (Agency for Health Care Policy and Research). Depression in primary care. Detection and diagnosis, vol. 1. Rockville: AHPCR, 1993, 124p.
3. ANAES (Agence Nationale d'Accréditation et d'Évaluation en Santé). Conférence de consensus: La crise suicidaire: reconnaître et prendre en charge. Paris: ANAES, 2000.
4. ANAES (Agence Nationale d'Accréditation et d'Évaluation en Santé). Conférence de consensus: Prise en charge d'un épisode dépressif isolé de l'adulte en ambulatoire. Paris: ANAES, 2002.
5. ANDEM (Agence Nationale pour le Développement de l'Évaluation Médicale). Recommandations et réfé rences pour la prescription des antidépresseurs. Paris: ANDEM, 1996, in Conc Med 1996; 42: 15p.
6. ANDERSON IM, TOMENSON BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. Br Med J 1995; 3, 310(6992): 1433-8.
7. ANDERSON IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anx 1998; 7 (1): 11-7.
8. APA, 1994. Diagnostic and statistical manual of mental disorders (DSM IV). Washington DC: APA, 1994.
9. ARTIGAS F, PEREZ V, ALVAREZ E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994; 51(3): 248-51.
10. BEASLEY CM Jr, DORNSEIF BE, BOSOMWORTH JC et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. Br Med J 1991; (21), 303(6804): 685-92.
11. BECH P, CIALDELLA P, HAUGH MC et al. Meta-analysis of randomised controlled trials of fluoxetine vs placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 2000; 176: 421-8.
12. BENNIE EH, MULLIN JM, MARTINDALE JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 1995; 56(6): 229-37.
13. BERMAN RM, ANAND A, CAPPIELLO A et al. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol Psychiatry 1999; 45(9): 1170-7.
14. BLAKELY RD, RAMAMOORTHY S, SCHROETER S et al. Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol Psychiatry 1998; 44(3): 169-78.
15. BLIER P, de MONTIGNY C, CHAPUT Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987; 7(6): 24-35.
16. COSTA e SILVA J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 1998; 59(7): 352-7.
17. CROWN WH, TREGLIA M, MENEADES L et al. Long-term costs of treatment for depression: impact of drug selection and guideline adherence. Value Health 2001; 4(4): 295-307.
18. DALERY J, BOUHASSIRA M, KRESS JP et al. Major agitated-anxious versus blunted-retarded depression: differential effects of fluoxetine. Encephale 1995; 21(3): 217-25.
19. DANTCHEV N, WIDLOCHER DJ. The measurement of retardation in depression. J Clin Psychiatry 1998; 59(14): 19-25.
20. DEVANE CL. Comparative safety and tolerability of selective serotonin reuptake inhibitors. Hum Psychopharmacol 1995; 10: 185-93.
21. DIAZ-MARTINEZ A, BENASSINNI O, ONTIVEROS A et al. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther 1998; 20(3): 467-76.
22. D'SA C, DUMAN RS. Antidepressants and neuroplasticity. Bipolar Disord 2002; 4(3): 183-94.
23. DUMAN RS, HENINGER GR, NESTLER EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54(7): 597-606.
24. ENTSUAH AR, HUANG H, THASE ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001; 62(11): 869-77.
25. FAVA M, ROSENBAUM JF, HOOG SL et al. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 2000; 59(2): 119-26.
26. FRANK L, REVICKI DA, SORENSEN SV et al. The economics of selective serotonin reuptake inhibitors in depression: a critical review. CNS Drugs 2001; 15(1): 59-83.
27. FUCHS E, FLUGGE G. Stress, glucocorticoids and structural plasticity of the hippocampus. Neurosci Biobehav Rev 1998; 23(2): 295-300.
28. GERETSEGGER C, BOHMER F, LUDWIG M. Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol 1994; 9(1): 25-9.
29. GREENBERG RP, BORNSTEIN RF, ZBOROWSKI MJ et al. A meta-analysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis 1994; 182(10): 547-51.
30. JOUVENT R, AMAR S. in Widlöcher. Traité de psychopathologie 1994. Paris: PUF, 1994: 166-7.
31. JOUVENT R. Physiopathologic hypotheses of depression. Encephale 2000; 26(n° Spec 5): 57-9.
32. JUDGE R, PLEWES JM, KUMAR V et al. Changes in energy during treatment of depression: an analysis of fluoxetine in double-blind, placebo-controlled trials. J Clin Psychopharmacol 2000; 20(6): 666-72.
33. KIRKER. Experimental design: procedures for the behavioral sciences. Wadsworth Publications, 1968.
34. LESCH KP. Serotonergic gene expression and depression: implications for developing novel antidepressants. J Affect Disord 2001; 62(1-2): 57-76.
35. MAES M, MELTZER HY. Psychopharmacology - The Fourth Generation of Progress. The American College of Neuropsychopharmacology, 2003.
36. MALBERG JE, EISCH AJ, NESTLER EJ et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000 15; 20(24): 9104-10.
37. MANJI HK, DREVETS WC, CHARNEY DS. The cellular neurobiology of depression. Nat Med 2001; 7(5): 541-7.
38. MAURICE-TISON S, VERDOUX H, GAY B et al. How to improve recognition and diagnosis of depressive syndromes using international diagnostic criteria. Br J Gen Pract 1998; 48(430): 1245-6.
39. MINTZ J, MINTZ LI, ARRUDA MJ et al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992; 49(10): 761-8.
40. NURNBERG HG, THOMPSON PM, HENSLEY PL. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatry 1999; 60(9): 574-9.
41. PATRIS M, BOUCHARD JM, BOUGEROL T et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996; 11(2): 129-36.
42. QUITKIN FM. Methodology of measuring the efficacy of antidepressants. Psychopharmacology 1992; 106: 87-9.
43. ROUILLON F, BLACHIER C, DREYFUS JP et al. Pharmaco-epidemiologic study of the use of antidepressant drugs in the general population. Encephale 1996; 22(1): 39-48.
44. RUDOLPH RL, FEIGER AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999; 56(2-3): 171-81.
45. RUTZ W, von KNORRING L, WALINDER J. Frequency of suicide on Gotland after systematic postgraduate education of general practitioners. Acta Psychiatr Scand 1989; 80(2): 151-4.
46. SHIRAYAMA Y, CHEN AC, NAKAGAWA S et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002 15; 22(8): 3251-61.
47. SILVERSTONE PH, RAVINDRAN A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999; 60(1): 22-8.
48. SURI RA, ALTSHULER LL, RASGON NL et al. Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. J Clin Psychiatry 2000; 61(12): 942-6.
49. SVENNINGSSON P, TZAVARA ET, WITKIN JM et al. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Nat Acad Sci USA 2002; 99(5): 3182-7.
50. THASE ME. Depression, sleep, and antidepressants. J Clin Psychiatry 1998; 59(4): 55-65.
51. TOLLEFSON GD, HOLMAN SL. Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression. Int Clin Psychopharmacol 1993; 8(4): 253-9.
52. TOLLEFSON GD, HOLMAN SL, SAYLER ME et al. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 1994; 55(2): 50-9.
53. TYLEE A, GASTPAR M, LEPINE JP et al. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 1999; 14(3): 139-51.
54. TYLEE A. Depression in the community: physician and patient perspective. J Clin Psychiatry 1999; 60(7): 12-6, 17-8.
55. Van PRAAG HM. Anxiety/aggression-driven depression. A paradigm of functionalization and verticalization of psychiatric diagnosis. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25(4): 893-924.
56. VERSIANI M, ONTIVEROS A, MAZZOTTI G et al. Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison. Int Clin Psychopharmacol 1999; 14(6): 321-7.
57. WHEATLEY DP, van MOFFAERT M, TIMMERMAN L et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry 1998; 59(6): 306-12.